The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus

Current Medical Research and Opinion

Volumn 32, Issue 8, 2016, Pages 1375-1385

  Alba, Maria ^a   Xie, John ^a   Fung, Albert ^a   Desai, Mehul ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Bone biomarkers; Bone mineral density; Canagliflozin; Fractures; SGLT2 inhibitor; Type 2 diabetes mellitus

Indexed keywords

BIOLOGICAL MARKER; CANAGLIFLOZIN; MINERAL; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; ANTIDIABETIC AGENT; CALCIUM;

ANTIDIABETIC ACTIVITY; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; FRACTURE; HUMAN; MINERAL BALANCE; MINERAL METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRECLINICAL STUDY; REVIEW; ANTAGONISTS AND INHIBITORS; BONE REMODELING; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM;

BONE DENSITY; BONE REMODELING; CALCIUM; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; FRACTURES, BONE; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84965013520     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2016.1174841     Document Type: Review

References (74)

1. S.Nair, J.P.Wilding Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010;95:34-42
2. M.A.Abdul-Ghani, L.Norton, R.A.DeFronzo Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011;32:515-31
3. J.J.Neumiller, J.R.WhiteJr, R.K.Campbell Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010;70:377-85
4. G.L.Bakris, V.A.Fonseca, K.Sharma, E.M.Wright Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009;75:1272-7
5. R.A.DeFronzo, J.A.Davidson, S.Del Prato The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012;14:5-14
6. J.Rosenstock, N.Aggarwal, D.Polidori,. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35:1232-8
7. J.P.Wilding The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism 2014;63:1228-37
8. E.M.Wright Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001;280:F10-8
9. J.Chen, S.Williams, S.Ho,. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther 2010;1:57-92
10. E.M.Wright, D.D.Loo, B.A.Hirayama Biology of human sodium glucose transporters. Physiol Rev 2011;91:733-94
11. L.Zhou, E.V.Cryan, M.R.D’Andrea,. Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1). J Cell Biochem 2003;90:339-46
12. Y.Liang, K.Arakawa, K.Ueta,. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 2012;7:e30555
13. D.Polidori, S.Sha, S.Mudaliar,. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 2013;36:2154-61
14. D.Devineni, C.R.Curtin, D.Polidori,. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 2013;53:601-10
15. T.Kissner, N.Doyle, R.Samadfam,. Bone as a target tissue in the toxicological assessment of anti-diabetes drug class of SGLT1 inhibitors. Presented at: 49th Annual Meeting of the Society of Toxicology; March 7–11, 2010; Salt Lake City, Utah. Abstract 117.
16. M.Tirmenstein, T.E.Dorr, E.B.Janovitz,. Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor. Int J Toxicol 2013;32:336-50
17. K.Ways, M.D.Johnson, R.N.V.S.Mamidi,. Successful integration of non-clinical and clinical findings in interpreting the clinical relevance of rodent neoplasia with a new chemical entity. Toxicol Pathol J 2015;43:48-56
18. R.N.V.S.Mamidi, J.Proctor, S.De Jonghe,. Carbohydrate malabsorption mechanism for tumor formation in rats treated with the SGLT2 inhibitor canagliflozin. Chem Biol Interact 2014;221:109-18
19. S.De Jonghe, J.Proctor, P.Vinken,. Carcinogenicity in rats of the antidiabetic SGLT2 inhibitor canagliflozin. Chem Biol Interact 2014;224:1-12
20. Food and Drug Administration. FDA Briefing Document. NDA 202293 Dapagliflozin tablets, 5 and 10 mg. Endocrinologic and Metabolic Drugs Advisory Committee Meeting. 19 July 2011. Available at: http://www.fda.gov/downloads/AdvisoryCommittee/UCM262994.pdf [Last accessed 11 January 2016]
21. European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP). European public assessment report (EPAR) for Jardiance (empagliflozin). EMEA/H/C/002677/0000. 20 March 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002677/WC500168594.pdf [Last accessed 11 January 2016]
22. S.Barone, S.L.Fussell, A.K.Singh,. Slc2a5 (Glut5) is essential for the absorption of fructose in the intestine and generation of fructose-induced hypertension. J Biol Chem 2009;284:5056-66
23. S.Sha, D.Devineni, A.Ghosh,. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS One 2014;9:e105638
24. B.Bode, K.Stenlöf, D.Sullivan,. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995) 2013;41:72-84
25. J.F.Yale, G.Bakris, B.Cariou,. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013;15:463-73
26. J.F.Yale, G.Bakris, B.Cariou,. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 2014;16:1016-27
27. N.Inagaki, K.Kondo, T.Yoshinari,. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab 2013;15:1136-45
28. H.Iijima, T.Kifuji, N.Maruyama, N.Inagaki Pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with type 2 diabetes mellitus. Adv Ther 2015;32:768-82
29. M.R.Weir, I.Kline, J.Xie,. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin 2014;30:1759-68
30. J.F.List, V.Woo, E.Morales,. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-7
31. D.E.Kohan, P.Fioretto, W.Tang, J.F.List Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014;85:962-71
32. E.Ferrannini, A.Berk, S.Hantel,. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 2013;36:4015-21
33. H.U.Haring, L.Merker, E.Seewaldt-Becker,. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014;37:1650-9
34. J.Rosenstock, A.Jelaska, C.Zeller,. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2015;17:936-48
35. B.Zinman, C.Wanner, J.M.Lachin,. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28
36. J.P.Bilezikian, N.B.Watts, K.Usiskin,. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. J Clin Endocrinol Metab 2016;101:44-51
37. H.E.Bays, R.Weinstein, G.Law, W.Canovatchel Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring) 2014;22:1042-9
38. O.Ljunggren, J.Bolinder, L.Johansson,. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2012;14:990-9
39. L.Hyldstrup, T.Andersen, P.McNair,. Bone metabolism in obesity: changes related to severe overweight and dietary weight reduction. Acta Endocrinol (Copenh) 1993;129:393-8
40. K.Bleicher, R.G.Cumming, V.Naganathan,. The role of fat and lean mass in bone loss in older men: findings from the CHAMP study. Bone 2011;49:1299-305
41. P.S.Hinton, R.S.Rector, M.A.Linden,. Weight-loss-associated changes in bone mineral density and bone turnover after partial weight regain with or without aerobic exercise in obese women. Eur J Clin Nutr 2012;66:606-12
42. A.V.Schwartz, K.C.Johnson, S.E.Kahn,. Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: results from the Look AHEAD randomized trial. J Bone Miner Res 2012;27:619-27
43. B.Bode, K.Stenlöf, S.Harris,. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes. Diabetes Obes Metab 2015;17:294-303
44. D.T.Villareal, L.Fontana, E.P.Weiss,. Bone mineral density response to caloric restriction-induced weight loss or exercise-induced weight loss: a randomized controlled trial. Arch Intern Med 2006;166:2502-10
45. J.Fleischer, E.M.Stein, M.Bessler,. The decline in hip bone density after gastric bypass surgery is associated with extent of weight loss. J Clin Endocrinol Metab 2008;93:3735-40
46. A.R.Skov, N.Haulrik, S.Toubro,. Effect of protein intake on bone mineralization during weight loss: a 6-month trial. Obes Res 2002;10:432-8
47. L.B.Jensen, F.Quaade, O.H.Sorensen Bone loss accompanying voluntary weight loss in obese humans. J Bone Miner Res 1994;9:459-63
48. W.T.Cefalu, L.A.Leiter, K.H.Yoon,. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941-50
49. N.B.Watts, J.P.Bilezikian, K.Usiskin,. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2016;101:157-66
50. ® (canagliflozin) tablets, for oral use [package insert]. Titusville, NJ, USA: Janssen Pharmaceuticals, 2015
51. US Food and Drug Administration. FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm [Last accessed 11 January 2016]
52. M.Nishimura, S.Naito Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet 2005;20:452-77
53. N.Harada, N.Inagaki Role of sodium-glucose transporters in glucose uptake of the intestine and kidney. J Diabetes Investig 2012;3:352-3
54. E.Ferrannini, S.J.Ramos, A.Salsali,. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217-24
55. M.Roden, J.Weng, J.Eilbracht,. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013;1:208-19
56. K.Stenlöf, W.T.Cefalu, K.A.Kim,. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-82
57. Forxiga (dapagliflozin) 5 mg and 10 mg film-coated tablets [summary of product characteristics]. Middlesex, United Kingdom: Bristol-Myers Squibb/AstraZeneca EEIG, 2014
58. INVOKANA (canagliflozin) tablets, for oral use [summary of product characteristics]. Beerse, Belgium: Janssen-Cilag International NV, 2015
59. Jardiance (empagliflozin) 10 mg film-coated tablets [summary of product characteristics]. Ingelheim, Germany: Boehringer Ingelheim GmbH, 2014
60. L.D.Quarles Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol 2012;8:276-86
61. S.I.Taylor, J.E.Blau, K.I.Rother SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 2015;100:2849-52
62. L.Rejnmark, P.Vestergaard, C.Brot, L.Mosekilde Increased fracture risk in normocalcemic postmenopausal women with high parathyroid hormone levels: a 16-year follow-up study. Calcif Tissue Int 2011;88:238-45
63. J.L.Hernandez, J.M.Olmos, E.Pariente,. Influence of vitamin D status on vertebral fractures, bone mineral density, and bone turnover markers in normocalcemic postmenopausal women with high parathyroid hormone levels. J Clin Endocrinol Metab 2013;98:1711-7
64. S.I.Taylor, J.E.Blau, K.I.Rother Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol 2015;3:8-10
65. C.P.Kovesdy, L.D.Quarles Fibroblast growth factor-23: what we know, what we don’t know, and what we need to know. Nephrol Dial Transplant 2013;28:2228-36
66. T.Larsson, R.Marsell, E.Schipani,. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 2004;145:3087-94
67. J.Arnlov, A.C.Carlsson, J.Sundstrom,. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 2013;83:160-6
68. M.A.Mirza, A.Larsson, H.Melhus,. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009;207:546-51
69. M.Wolf, M.Z.Molnar, A.P.Amaral,. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011;22:956-66
70. B.D.Parker, L.J.Schurgers, V.M.Brandenburg,. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010;152:640-8
71. H.M.Yamout, V.Perkovic, M.Davies,. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol 2014;40:64-74
72. H.D.Berlie, C.L.Garwood Diabetes medications related to an increased risk of falls and fall-related morbidity in the elderly. Ann Pharmacother 2010;44:712-7
73. M.S.Maurer, J.Burcham, H.Cheng Diabetes mellitus is associated with an increased risk of falls in elderly residents of a long-term care facility. J Gerontol A Biol Sci Med Sci 2005;60:1157-62
74. A.V.Schwartz, T.A.Hillier, D.E.Sellmeyer,. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 2002;25:1749-54